- Home
- SGC vs ITOS Comparison
SGC vs ITOS Comparison
Compare SGC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- ITOS
- Stock Information
- Founded
- SGC 1920
- ITOS 2011
- Country
- SGC United States
- ITOS United States
- Employees
- SGC N/A
- ITOS N/A
- Industry
- SGC Apparel
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGC Consumer Discretionary
- ITOS Health Care
- Exchange
- SGC Nasdaq
- ITOS Nasdaq
- Market Cap
- SGC 155.7M
- ITOS 381.2M
- IPO Year
- SGC N/A
- ITOS 2020
- Fundamental
- Price
- SGC $10.83
- ITOS $10.20
- Analyst Decision
- SGC Strong Buy
- ITOS Hold
- Analyst Count
- SGC 3
- ITOS 6
- Target Price
- SGC $17.00
- ITOS $10.60
- AVG Volume (30 Days)
- SGC 54.4K
- ITOS 836.6K
- Earning Date
- SGC 08-05-2025
- ITOS 08-07-2025
- Dividend Yield
- SGC 5.04%
- ITOS N/A
- EPS Growth
- SGC N/A
- ITOS N/A
- EPS
- SGC 0.45
- ITOS N/A
- Revenue
- SGC $563,931,000.00
- ITOS $35,000,000.00
- Revenue This Year
- SGC N/A
- ITOS N/A
- Revenue Next Year
- SGC $4.31
- ITOS N/A
- P/E Ratio
- SGC $24.71
- ITOS N/A
- Revenue Growth
- SGC 2.28
- ITOS 177.89
- 52 Week Low
- SGC $9.11
- ITOS $4.80
- 52 Week High
- SGC $20.75
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- SGC 58.87
- ITOS 65.94
- Support Level
- SGC $10.21
- ITOS $10.05
- Resistance Level
- SGC $11.28
- ITOS $10.21
- Average True Range (ATR)
- SGC 0.34
- ITOS 0.13
- MACD
- SGC 0.09
- ITOS -0.07
- Stochastic Oscillator
- SGC 72.26
- ITOS 96.67
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.